Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts - PubMed

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts - PubMed

pubmed.ncbi.nlm.nih.gov

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts - PubMed

Tyler M Seibert  1   2 ,
17-22 minutes

Comparative Study

doi: 10.1136/bmj.j5757.

Chun Chieh Fan  3   4 , Yunpeng Wang  5 , Verena Zuber  5   6 , Roshan Karunamuni  3   2 , J Kellogg Parsons  7 , Rosalind A Eeles  8   9 , Douglas F Easton  10 , ZSofia Kote-Jarai  8 , Ali Amin Al Olama  10   11 , Sara Benlloch Garcia  10 , Kenneth Muir  12   13 , Henrik Grönberg  14 , Fredrik Wiklund  14 , Markus Aly  14   15   16 , Johanna Schleutker  17   18   19 , Csilla Sipeky  17   18 , Teuvo Lj Tammela  20 , Børge G Nordestgaard  21   22 , Sune F Nielsen  21   22 , Maren Weischer  22 , Rasmus Bisbjerg  23 , M Andreas Røder  24 , Peter Iversen  21   24 , Tim J Key  25 , Ruth C Travis  25 , David E Neal  26   27 , Jenny L Donovan  28 , Freddie C Hamdy  26 , Paul Pharoah  29 , Nora Pashayan  30   29 , Kay-Tee Khaw  31 , Christiane Maier  32 , Walther Vogel  32 , Manuel Luedeke  32 , Kathleen Herkommer  33 , Adam S Kibel  34 , Cezary Cybulski  35 , Dominika Wokolorczyk  35 , Wojciech Kluzniak  35 , Lisa Cannon-Albright  36   37 , Hermann Brenner  38   39   40 , Katarina Cuk  38 , Kai-Uwe Saum  38 , Jong Y Park  41 , Thomas A Sellers  42 , Chavdar Slavov  43 , Radka Kaneva  44 , Vanio Mitev  44 , Jyotsna Batra  45 , Judith A Clements  45 , Amanda Spurdle  46   45   47 , Manuel R Teixeira  48   49 , Paula Paulo  48 , Sofia Maia  48 , Hardev Pandha  50 , Agnieszka Michael  50 , Andrzej Kierzek  50 , David S Karow  3   51 , Ian G Mills  5   52   26 , Ole A Andreassen  5 , Anders M Dale  1   51   53 , PRACTICAL Consortium*

Affiliations

Free PMC article

Comparative Study

Tyler M Seibert et al. BMJ. .

Free PMC article

Abstract

Objectives: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.

Design: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction of survival free from PCa.

Setting: Multiple institutions that were members of international PRACTICAL consortium.

Participants: All consortium participants of European ancestry with known age, PCa status, and quality assured custom (iCOGS) array genotype data. The development dataset comprised 31 747 men; the validation dataset comprised 6411 men.

Main outcome measures: Prediction with hazard score of age of onset of aggressive cancer in validation set.

Results: In the independent validation set, the hazard score calculated from 54 single nucleotide polymorphisms was a highly significant predictor of age at diagnosis of aggressive cancer (z=11.2, P<10-16). When men in the validation set with high scores (>98th centile) were compared with those with average scores (30th-70th centile), the hazard ratio for aggressive cancer was 2.9 (95% confidence interval 2.4 to 3.4). Inclusion of family history in a combined model did not improve prediction of onset of aggressive PCa (P=0.59), and polygenic hazard score performance remained high when family history was accounted for. Additionally, the positive predictive value of PSA screening for aggressive PCa was increased with increasing polygenic hazard score.

Conclusions: Polygenic hazard scores can be used for personalised genetic risk estimates that can predict for age at onset of aggressive PCa.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare no support from any organisation for the submitted work except as follows: DSK and AMD report a research grant from the US Department of Defense, OAA reports research grants from KG Jebsen Stiftelsen, Research Council of Norway, and South East Norway Health Authority, TMS reports honoraria from WebMD for educational content, as well as a research grant from Varian Medical Systems, ASK reports advisory board memberships for Sanofi-Aventis, Dendreon, and Profound, AK reports paid work for Certara Quantitative Systems Pharmacology, DSK reports paid work for Human Longevity, OAA has a patent application (US 20150356243) pending, AMD also applied for this patent application and assigned it to UC San Diego. AMD has additional disclosures outside the present work: founder, equity holder, and advisory board member for CorTechs Labs, advisory board member of Human Longevity, recipient of non-financial research support from General Electric Healthcare; no financial relationships with any companies that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1

Kaplan-Meier and Cox estimates of prostate cancer-free survival for patients in development set by centile ranges of polygenic hazard score. Centiles are in reference to distribution of score within 11 190 controls aged under 70 in development set. Time of “failure” is age at any diagnosis of prostate cancer. Controls were censored at age of observation. Formal testing of proportionality is described in appendix 1

Fig 2
Fig 2

Positive predictive value of PSA testing for aggressive PCa in validation set. Centiles refer to distribution of polygenic hazard score among young controls in development set. 95% confidence intervals are from random samples of cases in validation set (see methods)

None

Similar articles

Cited by 29 articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. 10.3322/caac.21262 - DOI - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. 10.1016/S0140-6736(14)60525-0 - DOI - PMC - PubMed
    1. Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society Prostate Cancer Advisory Committee American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98. 10.3322/caac.20066 - DOI - PubMed
    1. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V, Panel Members. European Society for Medical Oncology Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013;24:1141-62. 10.1093/annonc/mds624 - DOI - PubMed
    1. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P, Clinical Guidelines Committee of the American College of Physicians Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761-9. 10.7326/0003-4819-158-10-201305210-00633 - DOI - PubMed

 

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more